A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

Siegel, David S

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. [electronic resource] - Blood Oct 2012 - 2817-25 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

1528-0020

10.1182/blood-2012-05-425934 doi


Adult
Aged
Aged, 80 and over
Drug Resistance, Neoplasm
Female
Humans
Male
Middle Aged
Multiple Myeloma--drug therapy
Neoplasm Recurrence, Local--drug therapy
Neoplasm Staging
Oligopeptides--therapeutic use
Pilot Projects
Prognosis
Salvage Therapy
Survival Rate